PFIZER2026-01-012026-03-31PFIZER2026-03-31PFIZER2025-03-31PFIZER2025-04-012026-03-31PFIZER2026-01-012026-03-31in-capmkt:OtherExpenses1MemberPFIZER2025-04-012026-03-31in-capmkt:OtherExpenses1MemberPFIZER2026-03-31OtherNoncurrentFinancialAssetsDomain1PFIZER2026-03-31OtherNoncurrentFinancialAssetsDomain2PFIZER2026-03-31OtherNoncurrentAssetsDomain1PFIZER2026-03-31OtherNoncurrentAssetsDomain2PFIZER2026-03-31OtherCurrentFinancialAssetsDomain1PFIZER2026-03-31OtherCurrentAssetsDomain1PFIZER2026-03-31OtherNoncurrentFinancialLiabilitiesDomain1PFIZER2026-03-31OtherNoncurrentFinancialLiabilitiesDomain2PFIZER2026-03-31OtherCurrentFinancialLiabilitiesDomain1PFIZER2026-03-31OtherCurrentFinancialLiabilitiesDomain2PFIZER2026-03-31OtherCurrentLiabilitiesDomain1PFIZER2026-01-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss1PFIZER2025-04-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss1PFIZER2026-01-012026-03-31RelatedPartyTransactionDomain1PFIZER2025-12-31RelatedPartyTransactionDomain1PFIZER2026-03-31RelatedPartyTransactionDomain1PFIZER2026-01-012026-03-31RelatedPartyTransactionDomain2PFIZER2025-12-31RelatedPartyTransactionDomain2PFIZER2026-03-31RelatedPartyTransactionDomain2PFIZER2026-01-012026-03-31RelatedPartyTransactionDomain3PFIZER2025-12-31RelatedPartyTransactionDomain3PFIZER2026-03-31RelatedPartyTransactionDomain3PFIZER2026-01-012026-03-31RelatedPartyTransactionDomain4PFIZER2025-12-31RelatedPartyTransactionDomain4PFIZER2026-03-31RelatedPartyTransactionDomain4PFIZER2026-01-012026-03-31RelatedPartyTransactionDomain5PFIZER2025-12-31RelatedPartyTransactionDomain5PFIZER2026-03-31RelatedPartyTransactionDomain5PFIZER2026-01-012026-03-31RelatedPartyTransactionDomain6PFIZER2025-12-31RelatedPartyTransactionDomain6PFIZER2026-03-31RelatedPartyTransactionDomain6PFIZER2026-01-012026-03-31RelatedPartyTransactionDomain7PFIZER2025-12-31RelatedPartyTransactionDomain7PFIZER2026-03-31RelatedPartyTransactionDomain7PFIZER2026-01-012026-03-31RelatedPartyTransactionDomain8PFIZER2025-12-31RelatedPartyTransactionDomain8PFIZER2026-03-31RelatedPartyTransactionDomain8PFIZER2026-01-012026-03-31RelatedPartyTransactionDomain9PFIZER2025-12-31RelatedPartyTransactionDomain9PFIZER2026-03-31RelatedPartyTransactionDomain9PFIZER2026-01-012026-03-31RelatedPartyTransactionDomain10PFIZER2025-12-31RelatedPartyTransactionDomain10PFIZER2026-03-31RelatedPartyTransactionDomain10PFIZER2026-01-012026-03-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares500680PFIZERNOTLISTEDINE182A01018Pfizer LimitedMain BoardEquity2025-04-012026-03-312026-05-122026-05-05INRCroresQuarterlyFourth quarterSingle segmentPharmaceuticals2026-05-1213:30:002026-05-1218:30:00trueCash Flow IndirectDeclaration of unmodified opiniontruetrueNANAfalsetrue2025-01-31https://www.pfizerltd.co.in/files/Policy-on-Related-Party-Transactions_January-2025.pdffalsefalseNot Applicable2026-01-012026-03-31AuditedStandalone62923000004072000006699500000830400000117690000019630000077180000021100000147800000957400000410170000025978000009040000026882000006664000002360000069000000001998200000000019982000003800000020362000004575000001043.6843.680043.6843.681.The above financial results were reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on May 12, 2026. <BR> <BR> 2.The financial results of the Company have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended from time to time). <BR> <BR> 3.The financial results for the year ended March 31, 2026 have been audited by the statutory auditors of the Company. The audit opinion does not contain any modifications. The audit report will be filed with the Stock Exchanges and will also be available on the Company’s website - www.pfizerltd.co.in <BR> <BR> 4.Figures for the quarter ended March 31, 2026 and March 31, 2025 represent the difference between the audited figures in respect of the full financial year and published unaudited figures of nine months ended December 31, 2025 and December 31, 2024 respectively which were subject to a limited review by the statutory auditors. <BR> <BR> 5. Exceptional Items: <BR> <BR> a. Exceptional items of Rs.49.16 crore for the year ended March 31, 2026 includes <BR> <BR> i.The charge of Rs.41.73 crore for the year (nine months ended December 31, 2025 Rs.39.58 crore) towards personnel separation cost of field force and marketing teams as a result of an exclusive Supply and Marketing Agreement with Cipla Limited for marketing and distribution of four brands of the Company, viz., Corex Dx, Corex LS, Dolonex, and Neksium and also includes personnel separation cost for other support functions. <BR> <BR> ii.Effective 21 November 2025, the Government of India had consolidated several existing labour laws into a unified framework consisting of four Labour Codes, collectively known as the New Labour Codes. The Company has carried out an assessment based on the best available information and legal opinion, which has resulted in increase in the provision for employee benefits by Rs.7.43 crore for the year (nine months ended December 31, 2025 Rs.18.62 crore). The Company continues to monitor the developments pertaining to the New Labour Codes and the impact, if any, will be accounted in accordance with applicable accounting standards. <BR> <BR> b.Exceptional Items for the year ended March 31, 2025 relates to Net gain of Rs.172.81 crore (net of carrying value of Rs.31.75 crore and cost to sell - Premium and other charges Rs.59.84 crore, net of recovery) on account of assignment of Lease of MIDC Land and Sale of Building constructed on such land. <BR> <BR> 5.The Company has only one segment which is Pharmaceuticals. Therefore, disclosure relating to segments is not applicable and accordingly not made. <BR> 2025-04-012026-03-31AuditedStandalone2519650000018795000002707600000030951000006083900000-33590000036797000009480000057730000036328000001682770000010248300000-49160000097567000002575200000-42800000253240000007224300000000072243000003840000072627000004575000001041571500000157.92157.9200157.92157.92Other Expenses957400000Other Expenses36328000001361300000200000000052749000001435000000000001519000001519000007231000003331900000111866000004726600000018180000001026600000300810000000297000003295530000035030000038032200000004921880000045750000041571500000420290000004202900000000004340000004340000004810000000091500000025000000128300000203110000021594000001011900000319630000045620000030260000023197000000627480000000718980000049218800000Other non-current financial assets151900000Other non-current financial assets0Other tax assets (net)1663300000Other non-current assets1668600000Other current financial assets29700000Other current assets350300000Lease Liabilities360800000Other financial liabilities73200000Lease liabilities316500000Other current financial liabilities695400000Other current liabilities4562000000-2521000009060000003880000000006333000000005773000000-24440000001357000000001657000000140600000000-105000003214000000-2263000009530400000000-14530000009675700000000000001160000025230000000000000000000000017699000000-7145900000-5616700000000000000038170000075164000008500000000-7983100000-39241000000-392410000049507000001026600000Items that will not be reclassified subsequently to profit or loss5050000050500000Items that will not be reclassified subsequently to profit or loss51100000511000001250000012700000003800000038400000Pfizer Limited******Pfizer Service Company BVBA, Belgium******Fellow SubsidiaryPurchase of goods or servicesOn arms length basis and in Ordinary course of business2629800000-889600000-788300000Pfizer Limited******Pfizer Products India Private Limited******Fellow SubsidiarySale of goods or servicesOn arms length basis and in Ordinary course of business218300000386800000237100000Pfizer Limited******Pfizer export B.V******Fellow SubsidiarySale of goods or servicesOn arms length basis and in Ordinary course of business128000004120000012800000Pfizer Limited******Pfizer Worldwide Services Company******Fellow SubsidiarySale of goods or servicesOn arms length basis and in Ordinary course of business454500000190300000141400000Pfizer Limited******Pfizer Healthcare India Private Limited******Fellow SubsidiarySale of goods or servicesOn arms length basis and in Ordinary course of business425000004270000085200000Pfizer Limited******Pfizer Healthcare India Private Limited******Fellow SubsidiaryAny other transactionRent expensesOn arms length basis and in Ordinary course of business-2100000-3000000-5500000Pfizer Limited******John Wyeth & Brothers Ltd******Companies holding significant incfluenceAny other transactionBorrowingsOn arms length basis and in Ordinary course of business0-25000000-25000000Pfizer Limited******Pfizer Products India Private Limited******Fellow SubsidiaryAny other transactionReimbursement of expensesOn arms length basis and in Ordinary course of business-11200000-15100000-41300000Pfizer Limited******Pfizer Inc.******Ultimate Holding CompanyAny other transactionRecovery of expensesOn arms length basis and in Ordinary course of business380000003800000Pfizer Limited******John Wyeth & Brothers Ltd******Companies holding significant incfluenceAny other transactionRecovery of expensesOn arms length basis and in Ordinary course of business30000003000003348700000AuditedtrueB S R & Co. LLPtrue2028-07-31